These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10025446)

  • 21. Testosterone undecanoate: a new orally active androgen.
    Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current topics in testosterone replacement of hypogonadal men.
    Nieschlag E
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of male hypogonadotropic hypogonadism by pulsatile administration of gonadotropin-releasing hormones].
    von Werder K; Eversmann T
    Dtsch Med Wochenschr; 1984 Mar; 109(11):432-4. PubMed ID: 6365500
    [No Abstract]   [Full Text] [Related]  

  • 24. [Choice of treatment of erectile dysfunction associated with hypogonadism].
    Aliaev IuG; Vinarov AZ; Akhvlediani ND
    Urologiia; 2010; (4):37-8, 40-2. PubMed ID: 20967981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypogonadal men treated with oral testosterone undecanoate.
    Sarris S; Swyer GI; Lawrence DM
    Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hormone replacement therapy in men: practical aspects].
    Gamidov SI; Shcherbakov DV; Tazhetdinov OKh; Pavlovichev AA; Iremashvili VV
    Urologiia; 2011; (4):68, 70-3. PubMed ID: 22066247
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
    Mulhall JP; Valenzuela R; Aviv N; Parker M
    Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous and exogenous testosterone levels after administration of deuterium-labelled testosterone propionate in hypogonadotropic hypogonadism.
    Fujioka M; Shinohara Y; Baba S; Irie M; Inoue K
    Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):3100-1. PubMed ID: 2632058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 48,XXYY syndrome.
    Sørensen K; Nielsen J; Jacobsen P; Rølle T
    J Ment Defic Res; 1978 Sep; 22(3):197-205. PubMed ID: 568179
    [No Abstract]   [Full Text] [Related]  

  • 30. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.
    Leichtnam ML; Rolland H; Wüthrich P; Guy RH
    Pharm Res; 2006 Jun; 23(6):1117-32. PubMed ID: 16755346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xyosted--a testosterone auto-injector for hypogonadism.
    Med Lett Drugs Ther; 2019 Mar; 61(1567):37-38. PubMed ID: 30845097
    [No Abstract]   [Full Text] [Related]  

  • 33. Testosterone replacement therapy.
    Jones TH
    Br J Hosp Med (Lond); 2007 Oct; 68(10):547-53. PubMed ID: 17974303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [XX male syndrome].
    Schirren U
    Z Hautkr; 1983 Apr; 58(7):469-78. PubMed ID: 6408820
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
    El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
    J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 48,XXYY syndrome. Follow-up data on clinical characteristics and psychological findings in 4 patients.
    Borghgraef M; Fryns JP; Van den Berghe H
    Genet Couns; 1991; 2(2):103-8. PubMed ID: 1781953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pubertal induction in adult males with isolated hypogonadotropic hypogonadism using long-acting intramuscular testosterone undecanoate 1-g depot (Nebido).
    Santhakumar A; Miller M; Quinton R
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):155-7. PubMed ID: 23383861
    [No Abstract]   [Full Text] [Related]  

  • 40. A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate.
    Tschöp M; Behre HM; Nieschlag E; Dressendörfer RA; Strasburger CJ
    Clin Chem Lab Med; 1998 Apr; 36(4):223-30. PubMed ID: 9638347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.